And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is exceedingly modest. We plan to catch up on some reading, take a few naps, promenade with the official mascots, and hang with our shortest person. And what about you? You could cozy up in front of the telly and watch the Winter Olympics. Take in a moving picture. Or look into reserving a seat for that military parade we have heard about. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The budget deal struck by Congress left out a bill that is designed to prevent brand-name drug makers from using delay tactics to prevent cheaper generic competitors from coming onto the market, The Hill points out. Specifically, the CREATES Act would allow generic companies to file suit against brand-name rivals that do not provide samples of medicines needed to compile applications for obtaining regulatory approval. The bill is one of the few drug pricing measures that has bipartisan support in Congress.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy